ClinicalTrials.gg
RecruitingNCT06747858LunairCFUpdated May 8, 2026

Safety, Tolerability and Efficacy Study of ARCT-032 in People With Cystic Fibrosis

A Phase 2 interventional study of ARCT-032 in Cystic Fibrosis and CFTR Gene Mutation, sponsored by Arcturus Therapeutics, Inc.. Recruiting at 13 sites in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-05-08.

Sponsored by Arcturus Therapeutics, Inc. · Phase 2, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Dec 2024; still recruiting 1 year 11 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
33
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 717 studies in Cystic Fibrosis with a site in United States — 85 open to participants now, 111 under way, 8 of them phase 3. Cystic Fibrosis · United States.

Planned enrollment
268th of 517
33 · median 36
Started
2024
with 29 others
Phase 2
103 of 717
10 open now
Primary completion
2027-06
later than 47 of 108 live
Registered
684th of 717
by date

Among the 717 studies in Cystic Fibrosis with a site in United States, this one is the 268th largest by planned enrollment of the 517 interventional ones that give a count, is one of 30 that started in 2024, is one of 103 in phase 2, reaches primary completion later than 47 of the 108 other live ones, and was the 684th registered.

Cystic Fibrosis

1,622 studies on the registry are indexed under Cystic Fibrosis; 201 are open to participants now.

Browse Cystic Fibrosis studies →

Open to participants now

85 of the 717 studies in Cystic Fibrosis with a site in United States are open now. Recruiting first, the newest first:

80 more — sign in →

All 85 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 156 Cystic Fibrosis studies recruiting now, 95 (61%) set no upper age limit and 45 (29%) stop at 75 or younger; 87 take children under 18; 42 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 717 studies in Cystic Fibrosis with a site in United States, or all of them as a file.
02

Study summary

ARCT-032-02 is a Phase 2, open-label, multicenter, multiple-ascending dose study of ARCT-032 in adults with CF who are not eligible for CFTR modulator therapy or are not taking CFTR modulators due to drug intolerance, poor response, or lack of access to modulators.

Read the detailed description

This is an open-label, multiple-ascending dose study of ARCT-032 in adults with CF who are not on CFTR modulator therapy. After successful screening, eligible participants enrolled in cohorts 1-3 will receive nebulized ARCT-032 daily for 4 weeks and then will be followed for safety for a total of 12 weeks. In cohort 4, eligible participants will receive nebulized ARCT-032 for 12 weeks and will then be followed for safety for an additional 12 weeks.

03

Conditions studied

  • Cystic Fibrosis
  • CFTR Gene Mutation

Browse trials for

Keywords

  • CFTR
  • mRNA
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Eligibility criteria

Key Inclusion Criteria:

  1. Confirmed diagnosis of Cystic Fibrosis
  2. Not eligible for CFTR modulator therapy or not taking CFTR modulators for at least 60 days prior to dosing (e.g. due to intolerance, poor response, or lack of access to modulators)
  3. between 40% to 100% (cohorts 1-3) and 45% to 90% (cohort 4, inclusive) of predicted value for age, sex and height

Exclusion Criteria:

  1. History of illness or medical condition that might pose an additional risk or may confound study results
  2. Recent moderate or severe hemoptysis
  3. Recent major surgery
  4. Solid organ or hematologic transplant
  5. Requirement of supplemental oxygen while awake or > 2L per minute while sleeping.
  6. Chronic maintenance systemic exceeding equivalent of daily 15 mg oral prednisone or 30 mg every other day
  7. Adequate liver and kidney function as determined by lab tests
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Sequential assignment
Masking
None (open label)
Enrollment
33 participants (estimated)

Study arms

  • Experimental
    Cohort 1

    Dose Level A of ARCT-032, inhaled daily for 28 days

    Biological: ARCT-032

  • Experimental
    Cohort 2

    Dose Level B of ARCT-032, inhaled daily for 28 days

    Biological: ARCT-032

  • Experimental
    Cohort 3

    Dose Level C of ARCT-032, inhaled daily for 28 days

    Biological: ARCT-032

  • Experimental
    Cohort 4

    Dose level B or C of ARCT-032, inhaled once daily for 12 weeks

    Biological: ARCT-032

Interventions

  • BiologicalARCT-032

    CFTR mRNA formulated in lipid nanoparticles

06

What researchers measure

Primary outcomes

  1. Incidence, severity and dose relationship of adverse events

    Safety and tolerability of ARCT-032 assess by determining incidence, severity and dose-relationship of AEs by dose level

    Time frame: Cohorts 1-3: 16 weeks and Cohort 4: 24 weeks

Secondary outcomes

  1. Pharmacokinetics - Plasma Concentration

    Plasma concentration of ARCT-032 mRNA and lipid components

    Time frame: Up to 6 weeks

  2. Pharmacodynamics--Lung Function

    Change from baseline in FEV1

    Time frame: 4 weeks

  3. Pharmacodynamics--Cystic Fibrosis Quality of Life Questionnaire-Revised (CFQ-R)

    Change from baseline in CFQ-R RSS (Respiratory Symptoms Scale) Score. Overall CFQ-R score ranges from 0-100, with higher scores indicating better health.

    Time frame: 4 weeks

  4. High Resolution Computed Chromatography

    Changes from baseline to end of treatment in chest-HRCT-scan scores (e.g., airway wall thickness, air trapping, and mucus plugging scores)

    Time frame: 12 weeks

  5. EQ-5D-5L (Cohort 4 only)

    Change from baseline to end of treatment (Day 84) in EQ-5D-5L questionnaire scores

    Time frame: 12 weeks

07

Study locations

11 of 13 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Dec 2024 (actual). Primary completion is estimated for Jun 2027, 30 months after the start.

Of 40 industry-sponsored phase 2 interventional studies under Cystic Fibrosis, half reached primary completion within 15 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 29. This study's planned 30 months is above that.

Counting every sponsor, half of 57 studies reached it within 21 months; a quarter within 9 and three quarters within 34.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 17, 2024
First posted
Dec 24, 2024
StartActual
Dec 12, 2024
Primary completionEst.
Jun 2027
CompletionEst.
Jun 2027
Last update
May 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 8, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06747858
Lead sponsor
Arcturus Therapeutics, Inc.
Responsible party
Sponsor
First posted
Dec 24, 2024
Start date
Dec 12, 2024
Primary completion
Jun 2027 (estimated)
Completion
Jun 2027 (estimated)
Last update
May 8, 2026

Study contacts

Clinical Trial Disclosure Manager Central Email Box
Contact
CFclinicaltrials@arcturusrx.com
858-900-2660

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion